ADAPTIVE BIOTECHNOLOGIES CORPORATION Other Non-Current Liabilities
ADAPTIVE BIOTECHNOLOGIES CORPORATION (ADPT) had Other Non-Current Liabilities of $20.00 thousand as of 2026-06-30, per its 10-Q filed 2026-08-04.
Financial Statements › Balance Sheet › Liabilities › Liabilities, Noncurrent › Liabilities, Other than Long-Term Debt, Noncurrent
us-gaap:OtherLiabilitiesNoncurrent · last filed 2026-08-04
- 2026-06-30: Other Liabilities, Noncurrent $20.00K.
- 2026-03-31: Other Liabilities, Noncurrent $20.00K.
- 2025-12-31: Other Liabilities, Noncurrent $20.00K.
- 2025-09-30: Other Liabilities, Noncurrent $20.00K.
| Period end | Other Liabilities, Noncurrent |
|---|---|
| 2026-06-30 | $20.00K 10-Q · filed 2026-08-04 |
| 2026-03-31 | $20.00K 10-Q · filed 2026-05-05 |
| 2025-12-31 | $20.00K 10-Q · filed 2026-08-04 |
| 2025-09-30 | $20.00K 10-Q · filed 2025-11-05 |
| 2025-06-30 | $20.00K 10-Q · filed 2025-08-05 |
| 2025-03-31 | $20.00K 10-Q · filed 2025-05-01 |
| 2024-12-31 | $20.00K 10-K · filed 2026-02-26 |
| 2024-09-30 | $20.00K 10-Q · filed 2024-11-07 |
| 2024-06-30 | $20.00K 10-Q · filed 2024-08-01 |
| 2020-09-30 | $2.38M 10-Q · filed 2020-11-10 |
| 2020-06-30 | $1.50M 10-Q · filed 2020-08-10 |
| 2019-12-31 | $93.00K 10-K · filed 2021-02-24 |
| 2019-09-30 | $44.00K 10-Q · filed 2019-11-12 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| IOVANCE BIOTHERAPEUTICS, INC. (IOVA) | United States | $4.897B | -6.51 |
| CRISPR Therapeutics AG (CRSP) | $5.390B | -11.68 | |
| Relay Therapeutics, Inc. (RLAY) | United States | $3.884B | -14.30 |
| Scholar Rock Holding Corp (SRRK) | United States | $5.920B | -16.37 |
| CG Oncology, Inc. (CGON) | United States | $6.095B | -27.95 |
| Tarsus Pharmaceuticals, Inc. (TARS) | United States | $3.329B | -58.60 |
| Denali Therapeutics Inc. (DNLI) | United States | $3.274B | -8.04 |
| Beam Therapeutics Inc. (BEAM) | United States | $2.549B | -41.51 |
| Immunovant, Inc. (IMVT) | United States | $7.028B | -14.78 |
| Greenland Mines Ltd (GRML) | United States | $2.362B |